- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05520177
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
January 11, 2023 updated by: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
A Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of 601 Versus Ranibizumab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
To compare the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (601) with Ranibizumab in patients with macular edema secondary to BRVO
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
After a up to 14-day screening period, patients will be randomized allocated in 2 groups at 1:1 ratio and followed up for 52 weeks.
Followed-up visits will be scheduled at a 4-week interval.
After 6 initial monthly injections of 601 or ranibizumab (loading phase), subjects will enter an individualized flexible treatment (IFT) phase (week 24 to week 48).
During the IFT phase, subjects will receive either the injections or not based on the assessment of disease stability at each visit.
Efficacy and safety outcomes will be evaluated up to a period of 52 weeks.
Study Type
Interventional
Enrollment (Anticipated)
350
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gang Tong, Bachelor of Medicine
- Phone Number: 021-60790099
- Email: tonggang@3s-guojian.com
Study Locations
-
-
Beijing
-
BeiJing, Beijing, China, 100730
- Recruiting
- Beijing Hospital
-
Contact:
- Hong Dai, Bachelor
- Phone Number: 010-85133308
- Email: dai-hong@x263.net
-
Principal Investigator:
- Hong Dai
-
-
Guangdong
-
GuangZhou, Guangdong, China, 510630
- Recruiting
- The First Affiliated Hospital of Jinan University
-
Contact:
- JingXiang Zhong, MD
-
Principal Investigator:
- JingXiang Zhong
-
-
Henan
-
ZhengZhou, Henan, China, 450003
- Recruiting
- Henan Provincial Eye Hospital
-
Contact:
- Zongming Song, MD
-
Principal Investigator:
- Zongming Song
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Recruiting
- The Second Xiangya Hospital of Central South University
-
Contact:
- BaiHua Chen, MD
-
Principal Investigator:
- BaiHua Chen
-
-
Jiangsu
-
NanJing, Jiangsu, China, 210029
- Recruiting
- Jiangsu Province Hospital
-
Contact:
- SongTao Yuan, MD
-
Principal Investigator:
- SongTao Yuan
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Recruiting
- Shanghai General Hospital
-
Contact:
- Hong Wang, MD
-
-
Sichuan
-
ChengDu, Sichuan, China, 610000
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Fang Lu, MD
- Phone Number: 86-028-85422452
- Email: lufang@medicail.com.cn
-
Principal Investigator:
- Ming Zhang
-
-
Tianjin
-
TianJin, Tianjin, China, 300384
- Recruiting
- Tianjin Medical University Eye Hospital
-
Contact:
- Xiaorong Li, PhD
- Phone Number: 022-23346434
- Email: xiaorli@163.com
-
Principal Investigator:
- Xiaorong Li
-
Tianjin, Tianjin, China, 300020
- Recruiting
- TianJin eye hospital
-
Contact:
- QuanHong Han, MD
-
Principal Investigator:
- QuanHong Han
-
-
Zhejiang
-
HangZhou, Zhejiang, China, 310024
- Recruiting
- Zhejiang Province People's Hospital
-
Contact:
- MiaoQin Wu, MD
-
Principal Investigator:
- MiaoQin Wu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sign informed consent form and willing to be followed up at the time specified in the trial
- Male or Female, at least 18 years of age
- The study eye must meet the following criteria:Diagnosed with macular edema secondary to Branch retinal vein occlusion (BRVO) or Hemi-retinal vein occlusion (HRVO) within 12 months; BCVA score ≤ 73 and ≥19 letters using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/40 to 20/400); CRT ≥ 250μm; No optometric media opacity and pupil abnormal
- BCVA score ≥ 34 ETDRS letters (approximate Snellen equivalent of 20/200) in the fellow eye, with no active RVO disease.
Exclusion Criteria:
- For Study Eye: Concomitant conditions or ocular disorders in the study eye at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the 52-week study period
- For Study Eye: iris, chamber angle neovascularization or retinal, optic disc neovascularization
- For Study Eye: Previous use of intraocular or periocular steroids within 3 months prior to baseline, or dexamethasone intravitreal implant within 6 months prior to baseline
- For Study Eye: Macular laser photocoagulation (focal/grid),panretinal laser photocoagulation,vitrectomy,trabeculectomy or keratoplasty in the study eye at any time prior to baseline. YAG laser treatment or any other intraocular surgeries (e.g. cataract surgery) in the study eye within 3 months prior to the baseline
- For Study Eye: During the screening period, the BCVA is >10 letters improved
- For Study Eye: Aphakia (except IOL) or posterior capsular defect (except YAG posterior capsulotomy after intraocular lens implantation surgery)
- For Any Eye: Active ocular infections (e.g. blepharitis, conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in any eye
- For Any Eye: Uncontrolled glaucoma (defined as intraocular pressure after antiglaucoma therapy ≥ 25mmHg) in any eye, or the cup/disk ratio >0.8 in the study eye
- For Any Eye: History of intravitreal use of anti-VEGF drugs (e.g. ranibizumab,bevacizumab,aflibercept, conbercept, etc.) in any eye within 3 months prior to baseline
- History of allergy to fluorescein sodium and allergies to protein products for treatment or diagnosis
- History of stroke (cerebrovascular accident), myocardial infarction, active disseminated intravascular coagulation or pronounced bleeding tendency in the past 6 months prior to baseline
- Systemic immune diseases (e.g. ankylosing spondylitis, systemic lupus erythematosus, Behcet's disease, rheumatoid arthritis, scleroderma etc.)
- Any uncontrolled clinical conditions (e.g. AIDS, active hepatitis, serious mental, neurological, cardiovascular, respiratory and other systemic diseases or malignant tumors, etc.). Malignant tumors with no metastasis or recurrence within 5 years or cancers in situ cancers are not excluded.
- Uncontrolled blood pressure (defined as systolic blood pressure ≥ 160 mmHg or diastolic pressure ≥ 100 mmHg after antihypertensive medication
- History of surgery (except for healed minimally invasive surgery) and/or currently have unhealed wounds, moderate to severe ulcers, fractures, etc. within 1 month prior to baseline
- History of system use of anti-VEGF drugs (e.g. bevacizumab) within 3 months prior to baseline
- Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal value in the local laboratory). Renal function impairment (Cr is 1.5 times higher than the upper limit of normal values in the local laboratory)
- Abnormal coagulation function (prothrombin time ≥ the upper limit of normal value for 3 seconds) and activated partial thromboplastin time ≥ the upper limit of normal value for 10 seconds).
- Non-use of effective contraception during childbearing age (except for women with spontaneous admonishment of more than 12 months)
- Women in pregnancy and lactation
- Participation in clinical trials of any drug (except vitamins and minerals) or medical devices in the past 1 month or 5 half-lifes if the drug has a long half-life >1 month prior to baseline.
- Any conditions that researchers think it needs to be ruled out
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 601 1.25mg
loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
|
loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
Other Names:
|
Active Comparator: ranibizumab 0.5mg
loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
|
loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
best-corrected visual acuity (BCVA)
Time Frame: From Baseline to Week 24
|
Assessed with Early treatment diabetic retinopathy study (ETDRS) visual acuity testing charts.
|
From Baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
best-corrected visual acuity (BCVA)
Time Frame: up to 52 weeks
|
Assessed with Early treatment diabetic retinopathy study (ETDRS) visual acuity testing charts.
|
up to 52 weeks
|
central retinal thickness (CRT)
Time Frame: up to 52 weeks
|
SD-OCT (spectral domain optical coherence tomography) was used to assess the average retinal thickness of the central 1 mm diameter subfield around the foveal center.
|
up to 52 weeks
|
Number of injections
Time Frame: up to 52 weeks
|
Number of administered injections for 601 or ranibizumab
|
up to 52 weeks
|
Adverse Events (AEs)
Time Frame: up to 52 weeks
|
All adverse events related to 601 or ranibizumab observed through various tests (including blood routine, pregnancy test, electrocardiogram, etc.)
|
up to 52 weeks
|
Steady-state Blood concentrations of 601 or ranibizumab
Time Frame: up to 52 weeks
|
Detect the steady-state blood concentrations of 601 or ranibizumab through the subject's blood sample
|
up to 52 weeks
|
Blood concentrations of Vascular Endothelial Growth Factor (VEGF)
Time Frame: up to 52 weeks
|
Detect the blood concentrations of VEGF through the subject's blood sample
|
up to 52 weeks
|
anti-drug antibody (ADA) of 601
Time Frame: up to 52 weeks
|
Detect the presence of anti-drug antibody (ADA) of 601 through the subject's blood sample.
ADA-positive subjects will also undergo further Neutralization antibody (Nab) testing.
|
up to 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiaorong Li, MD, Tianjin Medical University Eye Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 27, 2022
Primary Completion (Anticipated)
December 1, 2025
Study Completion (Anticipated)
December 1, 2025
Study Registration Dates
First Submitted
August 26, 2022
First Submitted That Met QC Criteria
August 26, 2022
First Posted (Actual)
August 29, 2022
Study Record Updates
Last Update Posted (Estimate)
January 13, 2023
Last Update Submitted That Met QC Criteria
January 11, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Retinal Vein Occlusion
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- SSGJ-601-BRVO-III-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Branch Retinal Vein Occlusion
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
Palo Alto Medical FoundationTerminatedCentral Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Shahid Beheshti University of Medical SciencesLabbafinejad Medical CenterUnknownBranch Retinal Vein OcclusionIran, Islamic Republic of
-
He Eye HospitalUnknownBranch Retinal Vein OcclusionChina
-
Kyungpook National University HospitalCompletedBranch Retinal Vein OcclusionKorea, Republic of
-
Fukushima Medical UniversityUnknown
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
Medical University of ViennaRecruitingBranch Retinal Vein Occlusion | Retinal Blood Flow | Retinal Oxygen SaturationAustria
Clinical Trials on 601 1.25mg
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...UnknownBranch Retinal Vein OcclusionChina
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...UnknownCentral Retinal Vein OcclusionChina
-
Joanne Kurtzberg, MDAldagenWithdrawnLysosomal Storage Diseases | Inborn Errors of MetabolismUnited States
-
ADC Therapeutics S.A.TerminatedAdvanced Solid TumorsUnited States
-
C.B. Fleet Company, Inc.CompletedBowel Cleansing Prior to ColonoscopyUnited States
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting
-
Motric BioRecruitingStroke | Multiple Sclerosis | Cerebral Palsy | Spinal Cord Injuries | Dystonia | Muscle Spasticity | Hereditary Spastic Paraplegia | Hypertonia, MuscleUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
TransMolecularUnknownAstrocytoma | Glioblastoma Multiforme | Malignant Glioma | GBM | OligodendrogliomaUnited States
-
Erasca, Inc.Active, not recruitingAdvanced or Metastatic Solid TumorsUnited States